Literature DB >> 1656862

6-N-substituted derivatives of adenine arabinoside as selective inhibitors of varicella-zoster virus.

G W Koszalka1, D R Averett, J A Fyfe, G B Roberts, T Spector, K Biron, T A Krenitsky.   

Abstract

A series of 6-alkylaminopurine arabinosides were synthesized and found to inhibit varicella-zoster virus (VZV). The antiviral activities of these nucleosides were limited to VZV. None of the other viruses tested in the herpesvirus family were affected. The in vitro antiviral potencies of the 18 arabinosides correlated with their efficiencies as substrates of the VZV-encoded thymidine kinase in all but one case. The arabinosides of 6-methylaminopurine and 6-dimethylaminopurine were the most potent analogs, with 50% inhibitory concentrations against VZV of 3 and 1 microM, respectively. They were not cytotoxic to uninfected MRC-5 cells, human Detroit 98 cells, or mouse L cells (50% inhibitory concentration, greater than 100 microM). Neither 6-methylaminopurine arabinoside nor 6-dimethylaminopurine arabinoside was detectably phosphorylated by either adenosine kinase or 2'-deoxycytidine kinase. These two alkylaminopurine arabinosides were also resistant to deamination catalyzed by adenosine deaminase. The VZV-dependent phosphorylation of these nucleosides offers the possibility of a potent and highly selective therapy for VZV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656862      PMCID: PMC245186          DOI: 10.1128/AAC.35.7.1437

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus.

Authors:  D R Averett; G W Koszalka; J A Fyfe; G B Roberts; D J Purifoy; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Central nervous system toxicity with fludarabine.

Authors:  D E Merkel; N L Griffin; K Kagan-Hallet; D D Von Hoff
Journal:  Cancer Treat Rep       Date:  1986-12

3.  Synthesis and biological evaluations of certain 2-halo-2'-substituted derivatives of 9-beta-D-arabinofuranosyladenine.

Authors:  J A Secrist; A T Shortnacy; J A Montgomery
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

4.  Use of an enzyme-linked immunosorbent assay performed directly on fixed infected cell monolayers for evaluating drugs against varicella-zoster virus.

Authors:  F E Berkowitz; M J Levin
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

5.  Central nervous system toxicity of fludarabine phosphate.

Authors:  H G Chun; B R Leyland-Jones; S M Caryk; D F Hoth
Journal:  Cancer Treat Rep       Date:  1986-10

6.  In vitro susceptibility of varicella-zoster virus to acyclovir.

Authors:  K K Biron; G B Elion
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

7.  Progress curve analysis of adenosine deaminase-catalyzed reactions.

Authors:  T Spector
Journal:  Anal Biochem       Date:  1984-04       Impact factor: 3.365

8.  Formation and deamination of adenosine by cardiac muscle enzymes.

Authors:  H P Baer; G I Drummond; E L Duncan
Journal:  Mol Pharmacol       Date:  1966-01       Impact factor: 4.436

9.  Comparison of susceptibilities of varicella-zoster virus and herpes simplex viruses to nucleoside analogs.

Authors:  H Machida
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

10.  Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 2. Synthesis and activity of some nucleosides of 4-(alkylamino)-1H-pyrazolo[3, 4-d]pyrimidines.

Authors:  J L Rideout; T A Krenitsky; G W Koszalka; N K Cohn; E Y Chao; G B Elion; V S Latter; R B Williams
Journal:  J Med Chem       Date:  1982-09       Impact factor: 7.446

View more
  5 in total

1.  Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.

Authors:  G B Roberts; J A Fyfe; R K Gaillard; S A Short
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

2.  Metabolism and pharmacokinetics of the anti-varicella-zoster virus agent 6-dimethylaminopurine arabinoside.

Authors:  C U Lambe; A Resetar; T Spector; G W Koszalka; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 3.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431

4.  Anion exchange resins in phosphate form as versatile carriers for the reactions catalyzed by nucleoside phosphorylases.

Authors:  Julia N Artsemyeva; Ekaterina A Remeeva; Tatiana N Buravskaya; Irina D Konstantinova; Roman S Esipov; Anatoly I Miroshnikov; Natalia M Litvinko; Igor A Mikhailopulo
Journal:  Beilstein J Org Chem       Date:  2020-10-22       Impact factor: 2.883

Review 5.  Naturally Occurring and Artificial N9-Cytokinin Conjugates: From Synthesis to Biological Activity and Back.

Authors:  Hana Vylíčilová; Magdaléna Bryksová; Vlasta Matušková; Karel Doležal; Lucie Plíhalová; Miroslav Strnad
Journal:  Biomolecules       Date:  2020-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.